Undisclosed target for Amyotrophic Lateral Sclerosis

The term "Undisclosed target for Amyotrophic Lateral Sclerosis" refers to proprietary biological molecules currently being investigated as therapeutic targets in the pipeline of several biotechnology and pharmaceutical companies, most notably the collaboration between Merck & Co. (MSD) and Kineta, Inc. (formerly Yumanity Therapeutics) [2, 4]. These targets are typically identified through phenotypic screening or artificial intelligence platforms designed to isolate proteins that modulate the toxicity of misfolded or aggregated proteins like TDP-43, which are central to the pathology of ALS and frontotemporal dementia (FTD) [9, 11]. In the Merck/Kineta program, the target reached a validation milestone in 2023, confirming its potential to influence disease progression and leading Merck to assume full responsibility for its clinical development [2, 16]. Other prominent undisclosed ALS targets include PRX019, part of a collaboration between Prothena and Bristol Myers Squibb, which is aimed at broader neurodegenerative mechanisms [11, 16]. Because the identity of these targets is protected for intellectual property reasons, they represent "stealth" areas of high-value research focused on restoring motor neuron function and clearing toxic protein accumulation in the central nervous system.

Other names

Kineta ALS program targetMerck ALS program targetYumanity ALS targetPRX019 target programQurAlis undisclosed enzyme target

Modulation of protein misfolding, aggregation, or clearance pathways to maintain cellular proteostasis [4, 9].